Renal Safety of Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH): Findings from Clinical Trials and Global Real-World Experience (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #FR-PO0413; Pres time: Oct 23, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Conclusion Across clinical trials and in the real world, reported renal AEs were consistent with PNH and typical intercurrent illnesses, with no pattern identified over long-term follow-up. eGFR remained stable over up to 6 years in clinical trials, with no evidence of progressive kidney function decline."
Clinical • Real-world • Real-world evidence • Acute Kidney Injury • Cardiovascular • Chronic Kidney Disease • Complement-mediated Rare Disorders • Hematological Disorders • Infectious Disease • Nephrology • Paroxysmal Nocturnal Hemoglobinuria • Rare Diseases • Renal Disease • Thrombosis
|
|
Antonio Mastrangelo; María Gema Ariceta Iraola; Carla M. Nester; Anwesha Mukherjee; Peter Hillmen; Johan Szamosi; Liza Franzén; Ginny Taliadouros; Carlos M. de Castro; Regis Peffault de Latour
|